Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.68 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.68 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.68 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.68 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.68 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.68 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706371 | 0.99 | EGLN2 (0.69) | EGLN2EGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL2572490 | 0.85 | EGLN2 (0.53) | EGLN2EGLN1TET2OGFOD1TET1 | |
| SCHEMBL4752202 | 0.83 | EGLN2 (0.60) | EGLN2EGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL3703018 | 0.82 | EGLN2 (0.98) | EGLN2EGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL3708662 | 0.82 | EGLN2 (0.63) | EGLN2EGLN1TET2OGFOD1TET1 | |
| SCHEMBL29360570 | 0.81 | EGLN2 (1.00) | EGLN2EGLN1TET2OGFOD1TET1 | |
| SCHEMBL3703019 | 0.81 | EGLN2 (1.00) | EGLN2EGLN1TET2OGFOD1TET1 | |
| Hydrochloric Acid SCHEMBL3710476 | 0.81 | EGLN1 (0.59) | EGLN2EGLN1TET2OGFOD1TET1 | |
| SCHEMBL3708665 | 0.81 | EGLN2 (0.64) | EGLN2EGLN1TET2OGFOD1TET1 | |
| SCHEMBL3710480 | 0.80 | EGLN1 (0.60) | EGLN2EGLN1TET2OGFOD1TET1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9168249-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-28 | — | — | US | disclosed |
| US-8987261-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8653111-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| CN-103342696-A | Substituted dihydropyrazolon for treating cardiovascular and haematological diseases | BAYER HEALTHCARE AG | 2013-10-09 | — | — | CN | disclosed |
| CN-101631785-B | Substituted dihydropyrazolones for the treatment of cardiovascular and hematological disorders | BAYER IP GMBH | 2013-08-21 | — | — | CN | disclosed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-17 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| CN-101631785-A | Substituted dihydropyrazolones for the treatment of cardiovascular and hematological disorders | BAYER SCHERING PHARMA AG | 2010-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | CRBN 1487/4885EGLN2 250/4885EGLN1 828/4885 |
| US-20160229858-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | CRBN 1487/4885EGLN2 250/4885EGLN1 828/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | CRBN 2560/4885EGLN2 44/4885EGLN1 219/4885 |
| US-20120121727-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | CRBN 1487/4885EGLN2 250/4885EGLN1 828/4885 |
| US-20150148381-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | CRBN 1487/4885EGLN2 250/4885EGLN1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.